

Human Buserelin

Catalog No.: EB05838

Quantity: 0.1 mg

Concentration: 1.0 mg/ml

Background: Buserelin(Receptal) belongs to the group of gonadotrophin releasing hormone (gonadorelin) analogues (LHRH agonist). It acts on the pituitary gland which controls the amount of many different types of hormones (chemical messengers). Buserelin alters the amount of hormones, particularly the oestrogens androgens, this alteration of hormone levels can be exploited to treat cancers of the prostate gland, which are stimulated to grow by testosterone.

Format: **State:** Sterile Filtered White lyophilized (freeze-dried) powder.

Purity: Greater than 98.0% as determined by:

(a) Analysis by RP-HPLC.

(b) Anion-exchange FPLC.

(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.

Buffer System: Lyophilized from a concentrated solution in water containing no additives.

Endotoxin Level: Less than 0.1 ng/□g (IEU/□g) of Buserelin.

Reconstitution: It is recommended to reconstitute the lyophilized Buserelin in sterile 18MQ-cm H₂O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

Description: Buserelin(Receptal) belongs to the group of gonadotrophin releasing hormone (gonadorelin) analogues (LHRH agonist). It acts on the pituitary gland which controls the amount of many different types of hormones (chemical messengers). Buserelin alters the amount of hormones, particularly the oestrogens androgens, this alteration of hormone levels can be exploited to treat cancers of the prostate gland, which are stimulated to grow by testosterone.

AA Sequence:

Glu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH₂Et.

Storage: Lyophilized Buserelin although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution Buserelin should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

General References: 1. Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies. Gastroenterology 2007 Jan;132(1):45-51
2. Expression of monocyte chemotactic protein-1 in human endometrial cancer cells and the effect of treatment with tamoxifen or buserelin. J Int Med Res 2006 May-Jun;34(3):284-90
3. Comparison of outcome of clomiphene citrate/human menopausal

For research and in vitro use only. Not for diagnostic or therapeutic work.

Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Antibody Hotline - Technical Questions - Antibody Location Service
Free Call: 0800-2274746 (Germany only) - www.acris-antibodies.com

gonadotropin/cetrorelix protocol and buserelin long protocol--a randomized study. Gynecol Endocrinol 2006 Jun;22(6):297-302

4. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Eur Urol 2006 Sep;50(3):483-9

5. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Hum Reprod 2006 Jun;21(6):1408-15

6. Evaluation of the buserelin stimulation test in diagnosing gonadotropin deficiency in males with delayed puberty. J Pediatr 2006 Jan;148(1):89-94

PA1177XCME0607